# Metabolon Announces New Bioinformatics Application to Translate Metabolomic Biomarkers into Actionable Multiomic Hypotheses

- Link: https://www.thailand-business-news.com/pr-news/metabolon-announces-new-bioinformatics-application-to-translate-metabolomic-biomarkers-into-actionable-multiomic-hypotheses
- Published: 2026-10-20T20:00:00+07:00
- Author: PR Newswire

|   |

_New bioinformatics application combines curated metabolite-protein knowledge, advanced
network algorithms, interactive exploration, and optional AI interpretation to generate
clearer mechanistic hypotheses_

MORRISVILLE, N.C., Oct. 20, 2026 /PRNewswire/ — Metabolon, Inc., the global leader
in metabolomics solutions advancing life sciences research, diagnostics, therapeutics,
and precision medicine, today announced **Splash & Ripple**, a new bioinformatics
application within the company’s Integrated Bioinformatics Platform. Splash & Ripple
helps researchers translate metabolomic biomarkers into candidate protein mechanisms
and actionable multiomic hypotheses. 

Metabolomics captures biochemical activity close to phenotype, revealing the combined
effects of genes, protein activity, disease, treatment, and environmental influences.
While this proximity makes metabolomics highly informative, it can also complicate
interpretation. A changed metabolite may be associated with numerous enzymes, transporters,
receptors, and binding proteins, while conventional pathway enrichment often provides
broad biological context without identifying the specific mechanisms researchers
should investigate next. Moving from a metabolomics result to a focused mechanistic
hypothesis can therefore require extensive manual research across scientific literature,
biological databases, and multiple omics datasets. This process can take months,
even for teams with specialist expertise, creating a significant barrier to realizing
the full value of metabolomics. 

Splash & Ripple brings this work into a single exploratory environment. Starting
with a set of metabolomic biomarkers, the application identifies associated proteins
and traces their relationships through high-confidence interaction networks. Splash&
Ripple prioritizes candidate proteins based on the strength and concentration of
supporting metabolite evidence, allowing researchers to identify mechanisms supported
by multiple biochemical signals and examine the evidence behind those relationships.

"Metabolomics gives researchers an exceptionally powerful view of the biology that
governs the phenotypes researchers care about, but acting on that information has
required considerable time and specialist expertise," said Ro Hastie, President 
and CEO of Metabolon. "Splash & Ripple enables scientists to explore candidate protein
mechanisms immediately, understand why they have been prioritized, and develop more
focused multiomic hypotheses. Combined with our optional AI interpretation capability,
Splash & Ripple can accelerate work that might otherwise take months and help researchers
determine the most valuable next experiment."

At the foundation of Splash & Ripple is Metabolon’s proprietary **Metabolite Affiliated
Proteins (MAP) Database**, an exclusive, scientist-curated knowledge resource that
connects measured metabolites to enzymes, transporters, receptors, and binding proteins
through biologically meaningful relationships. Unlike conventional pathway-centered
analyses, the MAP Database extends beyond predefined annotations to reveal mechanistic
connections that may otherwise remain hidden. Built on Metabolon’s decades of metabolomics
expertise and supported by scientific literature and biological databases, this 
proprietary knowledge layer provides a uniquely powerful foundation for translating
biochemical signals into biological hypotheses. Splash & Ripple applies advanced
network algorithms to these curated relationships to identify proteins most closely
associated with observed metabolite changes, connect multiple biochemical signals,
and help researchers prioritize the mechanisms and experiments most likely to advance
discovery.

Additional Splash & Ripple supporting features include:

 ◦ An **optional AI-assisted interpretation module** that evaluates promising protein–
   metabolite relationships against literature, genetic associations, interaction
   evidence, and phenotypic context to generate citation-supported hypotheses for
   scientific review and refinement. Because AI is separate from the core analysis,
   organizations can use Splash & Ripple without AI when project requirements restrict
   AI usage. In either configuration, outputs support hypothesis generation and 
   experimental validation rather than establishing causality.
 ◦ Access to Metabolon’s **scientific services team** to help evaluate hypotheses,
   assess supporting evidence, and translate findings into actionable research plans,
   with support available based on project needs and scope.
 ◦ An **interactive interface** that lets researchers navigate among biomarkers,
   candidate proteins, and supporting network relationships to investigate potential
   mechanisms underlying observed biochemical changes.

Splash & Ripple is part of Metabolon’s Integrated Bioinformatics Platform, where
researchers can interpret metabolomics alongside genomic, transcriptomic, proteomic,
clinical, and other biological data. By linking metabolomic biomarkers to candidate
protein mechanisms using curated metabolite–protein knowledge, advanced network 
analysis, interactive exploration, and optional AI interpretation, Splash & Ripple
helps researchers quickly develop focused mechanistic hypotheses, prioritize downstream
experiments, and extract greater scientific and commercial value from metabolomics
and multiomics data.

To learn more about Splash & Ripple, visit [https://metabolon.com/bioinformatics-software/splash-and-ripple/](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4801385-1&h=3140798730&u=https%3A%2F%2Fmetabolon.com%2Fbioinformatics-software%2Fsplash-and-ripple%2F&a=https%3A%2F%2Fmetabolon.com%2Fbioinformatics-software%2Fsplash-and-ripple%2F)

**About MetabolomicsMetabolomics, the large-scale study of all small molecules in
a biological system, is the only omics technology that provides a complete current-
state functional readout of a biological system. Metabolomics helps researchers 
see beyond individual genetic variation, capturing the combined impact of genetic
and external factors, such as drugs, diet, lifestyle, and the microbiome, on human
health. By measuring thousands of discrete chemical signals that form biological
pathways in the body, metabolomics can reveal important biomarkers, enabling a better
understanding of a drug’s mechanism of action, pharmacodynamics, and safety profile,
as well as individual responses to therapy. Metabolomics anchors multiomic discovery
in biological function, helping organizations reduce uncertainty and make more confident
scientific and business decisions.

**About Metabolon[Metabolon](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4801385-1&h=4131500346&u=http%3A%2F%2Fwww.metabolon.com%2F&a=Metabolon),
Inc. is the global leader in metabolomics, with a mission to deliver biochemical
data and insights that expand and accelerate the impact of life sciences research
and complement other ‘omics’ technologies. With more than 25 years of metabolomics
leadership, 15,000+ projects, 4,000+ publications, and ISO 9001:2015, CLIA, and 
CAP certifications, Metabolon has developed industry-leading scientific, technological,
and bioinformatics techniques. Metabolon’s Global Discovery Panel is powered by 
the world’s largest proprietary metabolomics reference library, while Metabolon’s
expanding portfolio of solutions enables researchers to access Metabolon-standard
metabolomics through both centralized services and in-house workflows. The Metabolon
Verus™ Metabolomics Profiling Kit extends Metabolon’s validated methods into laboratories
worldwide, enabling researchers with LC-MS capabilities to generate standardized,
reproducible metabolomics data on-site through streamlined workflows, embedded quality
controls, automated compound annotation, and direct access to Metabolon’s Integrated
Bioinformatics Platform. Metabolon’s industry-leading data, translational science,
and bioinformatics expertise help customers and partners resolve some of the most
challenging questions in the life sciences, accelerating research and enhancing 
development success. The company offers scalable, customizable metabolomics and 
multiomics solutions—from discovery and targeted services to decentralized in-house
metabolomics—that support customer needs across academic research, biopharma, core
facilities, and CROs, from early discovery through clinical trials and product life-
cycle management. For more information, please visit [www.metabolon.com](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4801385-1&h=3406566928&u=http%3A%2F%2Fwww.metabolon.com%2F&a=www.metabolon.com)
and follow us on [LinkedIn](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4801385-1&h=3252373798&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2F39312&a=LinkedIn)
and [X](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4801385-1&h=1698000509&u=https%3A%2F%2Ftwitter.com%2FMetabolon&a=X).

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Metabolon Announces New Bioinformatics Application to Translate Metabolomic Biomarkers into Actionable Multiomic Hypotheses ](http://www.prnasia.com/story/archive/5075843_AE75843_0?rand=184833)
